3-chloro-4-nitrobenzophenone | 7501-56-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-4-nitrobenzophenone
• 英文别名: 3-Chlor-4-nitro-benzophenon；(3-Chloro-4-nitrophenyl)(phenyl)methanone；(3-chloro-4-nitrophenyl)-phenylmethanone
• CAS: 7501-56-6
• 化学式: C₁₃H₈ClNO₃
• mdl: MFCD00446581
• 分子量: 261.664
• InChiKey: DXFDGFNDWPFRSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-chloro-4-nitrobenzophenone 在 铁粉 (R,S)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamide 、 三乙胺 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 、 乙醇 、 二氯甲烷 为溶剂， 反应 20.5h， 生成 N-(4-benzoyl-2-cyanophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
  参考文献：
  名称：

  Chemical compounds and their use to elevate pyruvate dehydrogenase activity

  摘要：

  该化合物的使用公式（I）：其中：环C为苯基或碳链杂环芳基，选择自吡啶基、吡嗪基、嘧啶基和吡啶并吡嗪基；所述苯基或杂环芳基如本文所定义被取代；A—B选择自NHCO、OCH2、SCH2、NHCH2、反式乙烯基和乙炔基；R1与环C连接在与A—B连接位置的邻位碳上，如本文所定义；n为1或2；R2和R3为烷基、卤代烷基或如本文所定义的环烷基或卤代环烷基；描述了制造用于提高温血动物（如人类）PDH活性的药物。还描述了公式（I）化合物的盐和酯。

  公开号：

  US06369273B1
• 作为产物：
  描述：

  3-氯甲苯 在 三氯化铝 、 氯化亚砜 、 硫酸 、 硝酸 作用下， 以 苯 为溶剂， 反应 5.0h， 生成 3-chloro-4-nitrobenzophenone
  参考文献：
  名称：

  Synthesis and antiparasitic activity of albendazole and mebendazole analogues

  摘要：

  Albendazole (Abz) and Mebendazole (Mbz) analogues have been synthesized and in vitro tested against the protozoa Giardia lamblia, Trichomonas vaginalis and the helminths Trichinella spiralis and Caenorhabditis elegans. Results indicate that compounds 4a, 4b (Abz analogues), 12b and 20 (Mbz analogues) are as active as antiprotozoal agents as Metronidazole against G. lamblia. Compound 9 was 58 times more active than Abz against T. vaginalis. Compounds 8 and 4a also shown high activity against this protozoan. Compounds 4b and 5a were as active as Abz. None of the Mbz analogues showed activity against T. vaginalis. The anthelmintic activity presented by these compounds was poor. (C) 2003 Published by Elsevier Ltd.

  DOI：

  10.1016/s0968-0896(03)00497-8

文献信息

• Reactions of 1-(Benzotriazol-1-yl)-1-phenoxyalkane and (Benzotriazol-1-yl)ethoxyphenylmethane Anions with Nitroarenes: a New Approach to Alkyl and Aryl p-Nitroaryl Ketones
  作者：Alan R. Katritzky、Christophe Chassaing、Dorin Toader、Katherine Gill

  DOI：10.1039/a900891h

  日期：——

  p-Nitroaryl alkyl ketones and p-nitroaryl aryl ketones are prepared regioselectively by reactions of non-functionalized nitroarenes and benzotriazole stabilized carbanions.

  通过对非功能化硝基苯和苯并三氮唑稳定化碳负离子的反应，可选择性地制备p-硝基芳基烷基酮和p-硝基芳基苯基酮。
• Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide
  申请人：Zeneca Limited

  公开号：US05482969A1

  公开（公告）日：1996-01-09

  Compounds of formula I: ##STR1## wherein, ring C, A-B, R.sup.1, n, R.sup.2, and R.sup.3 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinary incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  公式I的化合物：其中，环C，A-B，R.sup.1，n，R.sup.2和R.sup.3具有规范中给定的任何含义，它们的药用盐在治疗尿失禁方面是有用的。还披露了制药组合物，制备公式I化合物和中间体的过程。
• Use of compounds for the elevation of pyruvate dehydrogenase activity
  申请人：AstraZeneca AB

  公开号：US06498275B1

  公开（公告）日：2002-12-24

  The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1 is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2 and R3 are as defined within; R4 is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.

  该公式（I）的化合物及其盐的使用；以及该公式（I）的药学上可接受的体内可降解前药；以及该化合物的药学上可接受的盐或前药：其中：环C是苯或与之相连的碳链杂环，其被定义为取代；R1是被定义为邻位取代基；n为1或2；A—B是被定义为连接基；R2和R3如所定义；R4是羟基、氢、卤素、氨基或甲基；用于制造用于提高温血动物（如人类）PDH活性的药物的描述。还描述了该公式（I）化合物的制备的药物组合物、方法和过程。
• Improvements in or relating to benzimidazoles
  申请人：ELI LILLY AND COMPANY

  公开号：EP0111993A2

  公开（公告）日：1984-06-27

  Certain N-substituted benzimidazoles, which are potent antiviral agents, are disclosed. The compounds are prepared by reacting the corresponding keto derivative with an alkylating agent or by cyclizing the corresponding o-phenylenediamine. Pharmaceutical formulations containing such compounds and a method of treating viral infections are provided.

  本研究公开了某些 N-取代的苯并咪唑，它们是有效的抗病毒剂。这些化合物是通过使相应的酮衍生物与烷化剂反应或使相应的邻苯二胺环化而制备的。还提供了含有此类化合物的药物制剂和治疗病毒感染的方法。
• Makosza,M.; Ludwikow,M., Roczniki Chemii, 1977, vol. 51, p. 829 - 833
  作者：Makosza,M.、Ludwikow,M.

  DOI：——

  日期：——